# Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma

> **NCT00433381** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 123 (actual)

## Conditions studied

- Adult Glioblastoma
- Adult Gliosarcoma
- Recurrent Adult Brain Neoplasm

## Interventions

- **BIOLOGICAL:** Bevacizumab
- **DRUG:** Irinotecan Hydrochloride
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT00433381
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03-01
- **Primary completion:** 2010-01-21
- **Final completion:** 2011-02-16
- **Target enrollment:** 123 (ACTUAL)
- **Last updated:** 2018-09-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00433381

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00433381, "Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00433381. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*